Larimar Therapeutics, Inc. - Director's Dealing 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ZAFGEN, INC. (ZFGN)
CIK: 0001374690
Period of Report: 2017-05-11

Reporting Person: Hughes Thomas E. (Director, President and CEO)

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-05-11	Common Stock	M	18928	$0.75	Acquired	83088	Direct
2017-05-11	Common Stock	M	6210	$0.75	Acquired	89298	Direct
2017-05-11	Common Stock	M	68073	$0.82	Acquired	157371	Direct

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-05-11	Stock Option (Right to Buy	$0.75	M	18928	Disposed	2018-12-15	Common Stock (18928)	Direct
2017-05-11	Stock Option (Right to Buy)	$0.75	M	6210	Disposed	2019-03-18	Common Stock (6210)	Direct
2017-05-11	Stock Option (Right to Buy)	$0.82	M	68073	Disposed	2020-03-10	Common Stock (68073)	Direct

F1: Includes 224 shares acquired under Zafgen, Inc.'s 2014 Employee Stock Purchase Plan on January 1, 2017.

F2: Fully vested.